medigraphic.com
ISSN 0016-3813 (Impreso)

2019, Número 2

<< Anterior Siguiente >>

Gac Med Mex 2019; 155 (2)


Linfoma anaplásico de células T grandes primario cutáneo CD30+. Serie de nueve casos

Ruiz-Arriaga LF, Landgrave-Gómez I, Toussaint-Caire S, Lacy-Niebla RM, Vega-Memije ME

Idioma: Español
Referencias bibliográficas: 37
Paginas: 130-135
Archivo PDF: 665.52 Kb.


RESUMEN

Introducción: El linfoma anaplásico de células T grandes CD30+ es un linfoma primario cutáneo en el cual no hay evidencia de enfermedad sistémica; para su diagnóstico es necesario el estudio histopatológico. Objetivo: Presentar los casos diagnosticados en el Departamento de Dermatología del Hospital General “Dr. Manuel Gea González” con linfomas anaplásicos de células T grandes primarios cutáneos CD30+ durante un periodo de 24 años. Método: Estudio retrospectivo en el que realizó estadística descriptiva. Se recopiló información de sexo, edad, características clínicas, resultados de pruebas complementarias, tratamientos previos y actuales, reportes de los estudios histopatológicos y de inmunohistoquímica. Resultados: Entre 29 309 expedientes, se encontraron nueve casos (0.000034 %) con diagnóstico de linfoma anaplásico de células T CD30+. Se hizo la confirmación del diagnóstico histopatológico e inmunohistoquímico por dos dermatopatólogos certificados. La edad promedio fue de 61.2 años, hubo predominio del sexo femenino y de lesión papular o nodular y topografía variada como presentación clínica inicial. Conclusiones: El pronóstico del linfoma anaplásico de células T grandes CD30+ en la población estudiada fue dependiente del estadio clínico. El tratamiento en etapas tempranas tiene resultados favorables.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cazzola M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood. 2016;127 2361-2364.

  2. Yu J, Blitzblau R, Decker R, Housman D, Wilsn L. Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results Database. J Clin Oncol. 2008; 26:1483-1488.

  3. Brown RA, Fernandez-Pol S, Kim J. Primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol. 2017;44:570-577.

  4. Kempf W, Pfaltz K, Vermeer M, Cozzio A, Ortiz-Romero P, Bagot M, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118:4024-4035.

  5. Yang S, Khera P, Wahlgren C, Ho J, Jukic D, Geskin L, et al. Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of alk-1 status: case reports and review of literature. Am J Clin Dermatol. 2011;12:203-209.

  6. Liu HL, Hoppe RT, Kohler S, Harvell J, Reddy S, Kim Y. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49:1049-1058.

  7. Vonderheid E, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol. 1996;34:470-481.

  8. Oliveira A, Fernandes I, Alves R, Lima M, Selores M. Primary cutaneous CD30 positive anaplastic large cell lymphoma: report of a case treated with bexarotene. Leuk Res. 2011;35:e190-e192.

  9. Sheehy O, Catherwood M, Pettengell R, Morris TC. Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis. Leuk Lymphoma. 2009;50:1389-1391.

  10. French LE, Shapiro M, Junkins-Hopkins JM, Vittorio CC, Rook AH. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. J Am Acad Dermatol. 2001;45:914-918.

  11. McGinnis K, Junkins-Hopkins J, Crawford G, Shapiro M, Rook A, Vittorio C. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol. 2004;50(3):375-379.

  12. Oregel K, Everett E, Zhang X, Nagaraj G. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. Expert Rev Anticancer Ther. 2016;16:279-283.

  13. Wehkamp U, Oschlies I, Nagel I, Brasch J, Kneba M, Günther A, et al. ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course. J Cutan Pathol. 2015;42 870‑877.

  14. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006;7:51-58.

  15. Rijlaarsdam JU, Huijgens PC, Beljaards RC, Bakels V, Willemze R. Oral etoposide in the treatment of cutaneous large-cell lymphomas. A preliminary report of four cases. Br J Dermatol. 1992;127:524-528.

  16. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496-5504.

  17. Benner M, Willemze R. Applicability and Prognostic Value of the New TNM Classification System in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol. 2009;145(12):1399‑1404.

  18. Bekkenk MW, Geelen FA, Van-Voorst-Vader PC, Heule F, Geerts M, Van-Vloten W, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653-3661.

  19. Booken N, Goerdt S, Klemke CD. Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry. J Dtsch Dermatol Ges. 2012;10:331-339.

  20. Artemi P, Wong DA, Mann S, Regan W. CD30 (Ki-1)-positive primary cutaneous T-cell lymphoma: report of spontaneous resolution. Australas J Dermatol. 1997;38:206-208.

  21. Biswas A, Tan B. Spontaneous regression of a childhood tumour with anaplastic histological features. Clin Exp Dermatol. 2012;38:318-320.

  22. Paulli M, Berti E, Rosso R, Boveri E, Kindl S, Klersy C, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin: clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol. 1995;13: 1343-1354.

  23. Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-3695.

  24. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105:3768-3785.

  25. DeCoteau JF, Butmarc JR, Kinney MC, Kadin M. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large cell lymphoma of nodal origin. Blood. 1996;87:3437-3441.

  26. Ishida M, Hodohara K, Yoshii M, Okuno H, Horinouchi A, Shirakawa A, et al. Primary cutaneous anaplastic large cell lymphoma occurring in an atopic dermatitis patient: a case report with review of the literature with emphasis on their association. Int J Clin Exp Pathol. 2014;7:1735-1741.

  27. Shimizu Y, Tanae K, Takahashi N, Kohri M, Arai E, Bessho M, et al. Primary cutaneous anaplastic large-cell lymphoma presenting with hemophagocytic syndrome: a case report and review of the literature. Leuk Res. 2010;34:263-266.

  28. Basheer A, Padhi S, Nagarajan R, Boopathy V, Mookkappan S, Igbal N. Hemophagocytic lymphohistiocytosis in association with primary cutaneous anaplastic large cell lymphoma. Case Rep Hematol. 2014; 2014:384123.

  29. Kang JH, Lee JH, Park HJ, Cho BK, Song CH, Ock SM, et al. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma arising in a patient with hypersensitivity to mosquito bites. Korean J Fam Med. 2015;36:35-41.

  30. Hirata Y, Yokote T, Nishiwaki U, Tsuji M, Hanafusa T. Syndrome of inappropriate antidiuretic hormone secretion associated with primary cutaneous anaplastic large cell lymphoma. Br J Haematol. 2012;157:412.

  31. Charafeddine KM, Farchoukh LO, Khalifeh I. Primary cutaneous anaplastic large-cell lymphoma occurring in a case of chronic myeloid leukemia in remission. J Cutan Pathol. 2012;39:884-886.

  32. Yanagi T, Shimizu T, Kodama K, Nemoto-Hasebe I, Kasai M, Shimizu H. CD30-positive primary cutaneous anaplastic large-cell lymphoma and definite squamous cell carcinoma. Clin Exp Dermatol. 2009;34:e293-e294.

  33. Newland KM, McCormack CJ, Prince H, Lade S. Cutaneous CD30 positive lymphoproliferative disorders with coexistent epithelial neoplasms: report of two cases. Australas J Dermatol. 2015;56:e83-e87.

  34. Zhou P, Geng S, Li B, Wang J, Wang X, Xiao S. Keratosis lichenoides chronica in association with primary cutaneous anaplastic large cell lymphoma. Int J Dermatol. 2014;53:e109-e112.

  35. Fletcher CL, Orchard GE, Hubbard V, Whittaker SJ, Edelson RL, Russell- Jones R. CD30(+) cutaneous lymphoma in association with atopic eczema. Arch Dermatol. 2004;140:449-454.

  36. Di-Lernia V, Viglio A, Cattania M, Paulli M. Carbamazepine-induced, CD30+, primary, cutaneous, anaplastic large-cell lymphoma. Arch Dermatol. 2001;137:675-676.

  37. Benner MF, Willemze R. Bone marrow examination has limited value in the staging of patients with an anaplastic large cell lymphoma first presenting in the skin. Retrospective analysis of 107 patients. Br J Dermatol. 2008;159:1148-1151.




2020     |     www.medigraphic.com